England’s NICE Backs Epidyolex For Seizures, Sativex For MS Spasticity
But New Guidance Rejects Cannabis-Based Drugs For Chronic Pain
Executive Summary
Health technology assessment body NICE has given the thumbs-up to Epidyolex and Sativex, which become the first plant-derived medicinal cannabis products to secure routine NHS funding. It has also issued positive guidance on other products including nabilone, but turned down the use of cannabis-based drugs in chronic pain.
You may also be interested in...
Deal Watch: Vir Partnering With Alnylam, WuXi On Coronavirus Treatments
US biotech expands 2017 collaboration with Alnylam and inks collaboration with WuXi. Plus deals involving AbbVie, Allergan, Amazon, Thermo Fisher, Qiagen, Boehringer Ingelheim, Trutino, Taiho, Arcus, Eisai, Fuji Yakuhin, Hikma, Glenmark, Hanmi, GC, Bayer, GW.
GW’s Cannabidiol Drug To Be Funded In England For Epilepsy
GW Pharma’s cannabidiol drug Epidyolex can be funded on the NHS in England for seizures in patients with Dravet syndrome or Lennox-Gastaut syndrome. The company will have to provide additional data to address a number of uncertainties, including the waning of treatment effect, while more safety data are expected from an ongoing study.
GW Pharmaceuticals Scores EU First For Cannabinoid Drug
GW Pharmaceuticals is pressing on with plans to launch its epilepsy treatment Epidyolex in the EU, starting with France and Germany.